Search
Search Results
-
Total-body [68 Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer
PurposeThe purpose of this study was to assess whether total-body [ 68 Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with...
-
The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy
Background and purpose[ 68 Ga]Ga-PSMA PET imaging has been extensively utilized for the detection of biochemical recurrence (BCR) in prostate cancer....
-
Retrospective analysis of thyroid incidentalomas detected by [68Ga]Ga-PSMA-11 PET/CT
BackgroundProstate cancer patients, undergo imaging procedures, with [ 68 Ga]Ga-PSMA-11 PET/CT (prostate-specific membrane antigen based positron...
-
[89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis
BackgroundThe state-of-the-art method for imaging men with biochemical recurrence of prostate cancer (BCR) is prostate-specific membrane antigen...
-
Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
RationaleIn patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA)...
-
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
BackgroundRoutine prostate-specific membrane antigen (PSMA) positron emission tomography (PET) performed for primary staging or restaging of prostate...
-
The image quality and feasibility of solitary delayed [68 Ga]Ga-PSMA-11 PET/CT using long field-of-view scanning in patients with prostate cancer
BackgroundPrevious studies have demonstrated that delayed [ 68 Ga]Ga-PSMA PET/CT imaging improves lesion detection compared to early [ 68 Ga]Ga-PSMA...
-
Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [68Ga]Ga-PSMA-11 PET/CT imaging: quantitative analysis of [68Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs
PurposeThis study aimed to quantitatively assess [ 68 Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs in prostate cancer using the...
-
Pre-treatment 68 Ga-PSMA-11 PET/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival
PurposeTo assess the prognostic value of pre-treatment [ 68 Ga]Ga-PSMA-11 PET/CT and other baseline clinical characteristics in predicting prostate...
-
Prediction of clinically significant prostate cancer by [68 Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance
PurposeIn our study, our aim was to investigate the role of [ 68 Ga]Ga-PSMA-11 PET /CT imaging in the diagnosis of clinically significant prostate...
-
Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis
BackgroundLiver uptake in [ 68 Ga]Ga-PSMA-11 PET is used as an internal reference in addition to clinical parameters to select patients for [ 177 Lu]Lu-P...
-
A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer
PurposeWe aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [ 68 Ga]Ga-P16-093 and [ 68 Ga]Ga-PSMA-11, in the...
-
Automated segmentation of lesions and organs at risk on [68Ga]Ga-PSMA-11 PET/CT images using self-supervised learning with Swin UNETR
BackgroundProstate-specific membrane antigen (PSMA) PET/CT imaging is widely used for quantitative image analysis, especially in radioligand therapy...
-
A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET/CT imaging
PurposeTo improve the diagnostic accuracy of initial detection in patients with suspected primary prostate cancer (PCa).
MethodsEighty-four patients...
-
Head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT in multiple myeloma
PurposeThe aim of this study was to compare [ 18 F]FDG and [ 68 Ga]Ga-PSMA-11 PET/CT image findings in patients with multiple myeloma (MM).
...
-
Prediction of T staging in PI-RADS 4–5 prostate cancer by combination of multiparametric MRI and 68Ga-PSMA-11 PET/CT
BackgroundIn this study, we explored the diagnostic performances of multiparametric magnetic resonance imaging (mpMRI), 68 Ga-PSMA-11 PET/CT and...
-
Total-body PET/CT with half-dose [68 Ga]Ga-PSMA-11 for biochemical recurrent prostate cancer: comparable diagnostic value to short axial field-of-view PET/CT with full-dose [68 Ga]Ga-PSMA-11
PurposeThe objective of this study was to evaluate the diagnostic performance and image quality of total-body positron emission tomography/computed...
-
Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer—a cross-sectional study
BackgroundCirculating-tumor DNA (ctDNA) and prostate-specific membrane antigen (PSMA) ligand positron-emission tomography (PET) enable...
-
Comparison of parametric imaging and SUV imaging with [68 Ga]Ga-PSMA-11 using dynamic total-body PET/CT in prostate cancer
PurposeStandardized uptake value (SUV) has been prevalently used to measure [ 68 Ga]Ga-PSMA-11 activity in prostate cancer, but it is susceptible to...
-
Comparison of quantitative whole body PET parameters on [68Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer
BackgroundPSMA PET/CT is a predictive and prognostic biomarker for determining response to [ 177 Lu]Lu-PSMA-617 in patients with metastatic castration...
